Ningbo Menovo Pharm Co Ltd - Asset Resilience Ratio
Ningbo Menovo Pharm Co Ltd (603538) has an Asset Resilience Ratio of 3.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Ningbo Menovo Pharm Co Ltd's Asset Resilience Ratio has changed over time. Check Ningbo Menovo Pharm Co Ltd (603538) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ningbo Menovo Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ningbo Menovo Pharm Co Ltd (603538) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥150.70 Million | 3.28% |
| Total Liquid Assets | CN¥150.70 Million | 3.28% |
Asset Resilience Insights
- Limited Liquidity: Ningbo Menovo Pharm Co Ltd maintains only 3.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ningbo Menovo Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ningbo Menovo Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Ningbo Menovo Pharm Co Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Ningbo Menovo Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.47% | CN¥216.82 Million ≈ $31.73 Million |
CN¥4.85 Billion ≈ $710.06 Million |
+1.15pp |
| 2024-12-31 | 3.32% | CN¥154.44 Million ≈ $22.60 Million |
CN¥4.65 Billion ≈ $680.62 Million |
-2.75pp |
| 2023-12-31 | 6.07% | CN¥268.65 Million ≈ $39.31 Million |
CN¥4.42 Billion ≈ $647.30 Million |
+1.15pp |
| 2022-12-31 | 4.92% | CN¥217.38 Million ≈ $31.81 Million |
CN¥4.42 Billion ≈ $646.71 Million |
-4.36pp |
| 2021-12-31 | 9.28% | CN¥371.38 Million ≈ $54.34 Million |
CN¥4.00 Billion ≈ $585.54 Million |
+4.93pp |
| 2020-12-31 | 4.35% | CN¥133.14 Million ≈ $19.48 Million |
CN¥3.06 Billion ≈ $448.17 Million |
+0.50pp |
| 2019-12-31 | 3.85% | CN¥100.60 Million ≈ $14.72 Million |
CN¥2.61 Billion ≈ $382.51 Million |
-12.80pp |
| 2017-12-31 | 16.65% | CN¥252.00 Million ≈ $36.88 Million |
CN¥1.51 Billion ≈ $221.50 Million |
+16.61pp |
| 2012-12-31 | 0.04% | CN¥350.50K ≈ $51.29K |
CN¥831.58 Million ≈ $121.69 Million |
-0.43pp |
| 2011-12-31 | 0.48% | CN¥3.37 Million ≈ $493.82K |
CN¥709.97 Million ≈ $103.89 Million |
-- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more